Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angioblast Systems Inc.

Division of Mesoblast Ltd.
www.angioblast.com

Latest From Angioblast Systems Inc.

Mesoblast acquires Angioblast to bring adult stem cell platform under one roof

Mesoblast of Australia is to acquire the remaining 67% stake in the privately held US firm Angioblast Systems that it does not already own, bringing commercial rights to an adult stem cell technology platform that both companies are working on under one umbrella.

Cardiovascular Orthopedics

US orphan status for Angioblast's stem cell therapy

The US FDAhas granted orphan status to Angioblast Systems' allogeneic mesenchymal precursor cell therapy for use in cancer patients receiving bone marrow transplants. The non-patient-specific cells will be used to regenerate damaged bone marrow and help transplants engraft in cases of insufficient haematopoietic stem cell production in patients with haematologic malignancies who have failed conventional chemotherapy. Angioblast is 39% owned by the Australian firm Mesoblast, which is developing various stem cell-based therapies (Scrip Online, August 18th, 2008).

Cancer Approvals

More promising results for Mesoblast's stem cell therapies

The Australian regenerative therapy company Mesoblasthas reported positive new clinical and preclinical data for its adult mesenchymal precursor cell (MPC) therapies in various orthopaedic and ophthalmic settings, paving the way for expanded clinical programmes and possible alliances.

Cardiovascular Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Ophthalmic
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mesoblast Ltd.
  • Senior Management
  • Elliott Bendrihem, CFO
    Carter Eckert, Chmn.
  • Contact Info
  • Angioblast Systems Inc.
    Phone: (212) 880-2060
    275 Madison Ave.
    4th Fl.
    New York, NY 10016
    USA
UsernamePublicRestriction

Register